Steel Dynamics Names Mark Millett As Chairman of the Board

Steel Dynamics, Inc. (NASDAQ:STLD) today announced that Mark D. Millett, a Company founder and its President and Chief Executive Officer, will also serve as the Chairman of the Board, effective immediately. Pursuant

Steel Dynamics, Inc. (NASDAQ:STLD) today announced that Mark D. Millett, a Company founder and its President and Chief Executive Officer, will also serve as the Chairman of the Board, effective immediately. Pursuant to the Company’s corporate governance policies, Keith E. Busse, also a Company founder, has stepped down as the Chairman of the Board to ensure an orderly transition of board leadership, and remains a director based on the results of the Company’s 2021 Annual Meeting of Shareholders held May 19, 2021. Mr. James C. Marcuccilli will remain the Company’s lead independent director.  

“Mark has done a tremendous job leading the Company,” stated Mr. Busse. “He has a clear strategic vision for Steel Dynamics and has demonstrated effective execution of this strategy. I believe Mark and the Steel Dynamics team will propel the Company forward through the next stage of growth. I am pleased to remain a director of the Board and to continue to participate in the great strides and opportunities we expect for the future.”

“On behalf of the Board of Directors, we would like to sincerely thank Keith for his contributions and valuable insights while serving since inception as our Chairman of the Board,” added Mark D. Millett, President and Chief Executive Officer. “His expertise in the industry, multitude of business relationships and wise judgment have been instrumental in guiding Steel Dynamics through many business and developmental milestones. I look forward to continuing to work closely with Keith as a director of our Board.”

Total
0
Shares
Related Posts
Read More

Cellectis Reported Proprietary Product Candidate UCART22 was Administered after Lymphodepletion with Fludarabine, Cyclophosphamide and Alemtuzumab (FCA) with no Dose-Limiting Toxicities in BALLI-01 Phase 1 Study at ASH 2021; Said Preliminary Data Demon…

Cellectis (Nasdaq: CLLS), a clinical-stage biotechnology company employing its pioneering TALEN® gene-editing platform to develop innovative therapeutics for the treatment of serious diseases, announced today preliminary results from the BALLI-01 Phase 1 study of UCART22, its allogeneic CAR-T cell therapy candidate target

CLLS